Phenylephrine

The FDA has proposed an order for the removal of oral phenylephrine as an active ingredient from over-the-counter monograph drug products for relieving nasal congestion, according to an administration press release.

An FDA advisory panel has deemed oral phenylephrine, an ingredient in many cold and allergy medications sold over the counter to treat decongestion, no more effective than placebo.

Omidria qualifies for separate payment in ASCs under the CMS policy for non-opioid pain management surgical drugs when used in the ASC setting, according to an Omeros press release.

Dropless or reduced drop cataract surgery can improve patient compliance, reduce costs, reduce ocular surface damage, and increase patient satisfaction and convenience, according to a speaker.

Omeros Corporation’s 2-year extension of pass-through status for Omidria provided by Congress through the Consolidated Appropriations Act of 2018 expired Oct. 1.

There are benefits to using Omidria during pediatric cataract surgery, including in infants, according to a study.

Several CMS-designated permanent and product-specific J-codes recently went into effect, allowing three ophthalmology-minded pharmaceutical companies to expand reimbursement through commercial and Medicare insurance plans.

Significantly fewer patients undergoing cataract surgery who received intracameral Omidria experienced severe pain or required intraoperative fentanyl than did patients who received epinephrine, according to a study.

SAN FRANCISCO — Eric Donnenfeld, MD, discusses a recent study of Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution, Omeros) at the American Academy of Ophthalmology meeting. Results found 90% of patients treated with Omidria were less likely to need opioids during surgery.